Register
Login:
Share:
Email Facebook Twitter


Tech company Mporium delivers an outstanding set of Q1 results says CEO De Groot
IronRidge Resources CEO hails spectacular lithium project and money making potential for gold




Share Price Information for N4 Pharma Plc (N4P)


Share Price: 4.15Bid: 4.10Ask: 4.20Change: 0.00 (0.00%)No Movement on N4 Pharma Plc
Spread: 0.10Spread as %: 2.44%Open: 4.20High: 0.00Low: 0.00Yesterday’s Close: 4.15

N4 Pharma Plc Ord 0.4P

N4 Pharma Plc is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
4.15
Share Price SpacerBid
4.10
Share Price SpacerAsk
4.20
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
0
Share Price SpacerOpen
4.20
Share Price SpacerHigh
0.00
Share Price SpacerLow
0.00
Share Price SpacerClose
4.15
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 101.46m £4.21m 30,000

52 Week High 28.50 52 Week High Date 18-JUN-2018
52 Week Low 3.35 52 Week Low Date 20-SEP-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -1.463 -2.84 0.00 0.00


London South East Users info for N4 Pharma Plc




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

18-Apr-19
14:26:01
4.11
300,000
Sell* 
4.10
4.30
12.33k
Trade Type:
Ordinary

18-Apr-19
13:22:13
4.11
18,275
Sell* 
4.10
4.30
751.10
Trade Type:
Ordinary

18-Apr-19
08:41:58
4.11
12,000
Sell* 
4.10
4.30
493.20
Trade Type:
Ordinary




View more N4 Pharma Plc trades >>

Directors Deals for N4 Pharma Plc (N4P)
Trade DateActionNotifierPriceCurrencyAmountHolding
10-Apr-19Buy
Trade Notifier Information for N4 Pharma
Nigel Theobald held the position of CEO at N4 Pharma at the time of this trade.
 Nigel Theobald
4.44GBX67,34312389919
10-Apr-19Buy
Trade Notifier Information for N4 Pharma
Nigel Theobald held the position of CEO at N4 Pharma at the time of this trade.
 Nigel Theobald
44.4GBX67,34312389919
10-Nov-17Buy
Trade Notifier Information for N4 Pharma
Nigel Theobald held the position of CEO at N4 Pharma at the time of this trade.
 Nigel Theobald
7.92GBX56,65612255233
View more N4 Pharma Plc directors dealings >>


Vander
Posts: 406
Opinion:No Opinion
Price:4.20
RE: expecting a fall... but how low?
Wed 09:12
The Eu-ncl characterisation process is independent and should be ongoing in addition to the manufacturing scale up

They have put all non essential clinical studies on hold until the UQ testing conditions are fully documented- otherwise they will keep getting inconsistent results
waccybaccy
Posts: 159
Opinion:No Opinion
Price:4.25
RE: expecting a fall... but how low?
Tue 19:21
True, now maybe the EUNCL stuff is what they meant by "other commitments".
99treble
Posts: 2,613
Opinion:No Opinion
Price:4.20
RE: expecting a fall... but how low?
Tue 14:14
Or have they been put on hold re the latest RNS until they iron out the UofA results.
waccybaccy
Posts: 159
Opinion:No Opinion
Price:4.35
RE: expecting a fall... but how low?
Mon 23:06
Been thinking about this. We also have the EUNCL trials going on and IIRC the results from that are due Q4 this year. Let's hope they conveyed the correct test environment to them!
Purdey
Posts: 946
Opinion:No Opinion
Price:4.35
RE: expecting a fall... but how low?
Mon 16:39
Almost feels like delay tactics at work IMO, but surely not..
View more share chat for N4 Pharma Plc (N4P) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk











Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.